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Abstract 
Objectives We examined the prognostic value of first-phase ejection fraction (EF1) in 
patients with aortic stenosis (AS), a condition in which left ventricular dysfunction as 
measured by conventional indices is an indication for valve replacement.  
Background EF1, the ejection fraction up to the time of maximal ventricular contraction may 
be more sensitive than existing markers in detecting early systolic dysfunction. 
Methods The predictive value of EF1 compared to conventional echocardiographic indices 
for outcomes was assessed in 218 asymptomatic patients with at least moderate AS, including 
73 with moderate, 50 with severe and 96 with “discordant” (aortic area < 1.0 cm2 and gradient 
< 40 mmHg) AS, all with preserved EF, followed for at least 2 years. EF1 was measured 
retrospectively from archived echocardiographic images by wall tracking of the endocardium. 
The primary outcome was a combined event of aortic valve intervention, hospitalisation for 
heart failure and death from any cause.  
Results EF1 was the most powerful predictor of events in the total population and all sub-
groups. A cut-off value of 25% gave hazard ratios (for EF1<25% compared to ≥25%) of 27.7, 
(95% confidence interval 13.1-58.7, P<0.001) unadjusted, and 24.4 (11.3-52.7, P<0.001) 
adjusted for other echocardiographic measures including global longitudinal strain, for events 
at 2-years in all patients with asymptomatic AS. Corresponding hazard ratios for all-cause 
mortality in the total population were 17.5 (5.7-53.3) and 17.4 (5.5-55.2) unadjusted and 
adjusted respectively.  
Conclusion EF1 may be potentially valuable in the clinical management of patients with AS 
and other conditions in which there is progression from early to late systolic dysfunction. 
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Introduction 
Aortic stenosis (AS) is the most common form of primary heart valve disease in more 
economically developed countries, with a prevalence of moderate or severe disease of 
approximately 3%  aged ≥75  (1). It is often asymptomatic but when symptoms develop 
and/or there is a reduction in left ventricular (LV) ejection fraction (EF), survival without 
intervention is poor (2). Symptoms or reduced EF are thus Class I indications for aortic valve 
replacement (AVR) in severe AS while the management of asymptomatic severe AS remains 
less certain (3-5), particularly for patients in whom measures of AS severity by valve area and 
pressure gradient are “discordant” (6,7). The mortality soon after the onset of symptoms 
before surgery can be performed is up to 15% (8). An objective measurement that predicts 
impairment in EF and/or imminent onset of symptoms would thus be invaluable in selecting 
high-risk asymptomatic patients with preserved EF for more frequent clinical monitoring or 
early surgical intervention.  
The biophysics of myocyte contraction suggest that, when systolic function is 
impaired early in systole, a mechanism may exist to preserve overall LV EF at the expense of 
a slower sustained contraction (9-11). A novel measure of early ejection fraction is the first-
phase ejection fraction (EF1, Figure 1), the ejection fraction up to the time of maximal 
ventricular fibre shortening. This may be a fundamental characteristic of LV function that 
determines subsequent events in systole via mechanosensing (10).  In a pilot study, we 
observed a marked impairment of EF1 in AS, despite preserved overall EF. EF1 was inversely 
related to the severity of the AS suggesting it could be a sensitive prognostic marker of future 
systolic function and subsequent events in AS.  The purpose of the present study was to 
examine the value of EF1 in predicting the onset of symptoms requiring valve intervention or 
major events in a cohort of patients with moderate to severe AS.  We compared EF1 with 
conventional measures of valve and LV function. 
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Methods 
Patient population 
A retrospective study of the predictive value of EF1 for major adverse cardiovascular events 
was undertaken in consecutive asymptomatic patients with at least moderate AS seen in a 
specialist valve clinic at Guy’s and St Thomas’ Hospital between January 2008 and December 
2015 using anonymised data from the Guy’s and St Thomas’ Valve Study Group. This 
included demographics, symptoms and risk factors including smoking, hypertension, diabetes, 
coronary artery disease (defined as a history of angina pectoris or evidence of a > 50% 
coronary artery stenosis on angiography) and chronic kidney disease as well as outcome data 
for all patients.  
All patient clinical records were entered in a hospital digital database (Electronic 
Patient Record, iSOFT Group, Aldershot, UK).  Outcome data were verified from Hospital 
records. Symptoms were carefully evaluated by one of the authors (JC) at the time of 
presentation and for patients in whom symptoms were uncertain, an exercise tolerance test 
was performed. Inclusion criteria comprised asymptomatic AS of at least moderate severity 
with LV EF ≥ 50%. Exclusion criteria included: resting arrhythmia, more than moderate 
disease of other valves, lost to follow-up and suboptimal ultrasound images. The primary 
outcome was a combination of aortic valve intervention (as a result of developing symptoms 
or EF < 50%), hospitalisation for heart failure and all-cause mortality. All-cause mortality 
was examined as a secondary outcome.  
Echocardiography and first phase ejection fraction 
Transthoracic echocardiography was performed with patients at rest using a GE Vivid 7 
ultrasound platform (GE Healthcare, Andover, USA). All echocardiographic measurements 
were performed using standard techniques according to the recommendations of the American 
society of Echocardiography (12). LV mass was measured from a two-dimensional 
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parasternal view according to ASE recommendations. LV mass index (LVM/LVMi) was 
calculated by dividing LVM by body surface area (BSA). Left atrial (LA) volume was 
measured by tracing the LA border from apical 4 and 2 chamber views and left atrial volume 
index (LAVi) obtained by indexing LA volume to BSA. Stroke volume was calculated as 
volume difference between ED and ES and indexed to BSA to give stroke volume index 
(SV/SVi).  Trans-aortic flow rate (TAFR) was defined as stroke volume over ejection time 
(ET). Tissue Doppler measures were obtained at levels of the lateral and septal mitral annulus 
to obtain an optimal spectral Doppler waveform. The E/e’ ratio was calculated as a measure 
of diastolic function from the ratio of the transmitral Doppler E wave velocity to the mean of 
basal lateral and septal tissue Doppler e’ waves (13).  Effective aortic orifice area was 
calculated using the continuity equation and indexed to BSA (AVA/AVAi).  Moderate AS 
was defined as peak AV velocity 3.0-4.0m/s, mean pressure gradient (MPG) 20-40mmHg, 
and AVA 1.0-1.5cm2; severe AS was defined as peak AV velocity > 4.0m/s, MPG 
>40mmHg, and aortic valve area <1.0cm2. Patients with MPG<40mmHg and AVA<1.0cm2 
were defined as “discordant” (6,7). Current algorithms (14,15) further divide this discordant 
group by SVi with a cut-point of 35 mL/m2 as a surrogate for flow.  In this study, we divided 
them by calculated trans-aortic flow rate (< and > 200mL/ms) (16) as well as SVi and also by 
EF1 and global longitudinal strain (GLS) as further measures of LV dysfunction using cut-
points derived from receiver-operating characteristic (ROC) curve analysis as described 
below. 
The additional image analysis was performed by two authors whilst blinded to clinical 
outcomes on archived images using the EchoPAC analysis package (EchoPAC, GE 
Healthcare, Guildford, UK). GLS was measured by from speckle tracking echocardiography 
by placing 6 points along endocardial border and adjusting the width of interest to 
accommodate myocardial thickness from apical 4, 2 and 3 chamber views. LV volumes were 
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measured by 2D Simpson’s method from apical 4 and 2 chamber views at end-diastole, time 
of peak aortic valve flow and end-systole. Ejection Fraction (EF) was calculated as the 
percentage change of LV volume from end-diastole to end-systole.  EF1 was taken as the 
percentage change in LV volume from end-diastole to the time of peak AV flow (TPAVF, 
Figure 1), a time that approximates the time of peak ventricular contraction in individual 
myocytes.  EF1 was thus given by: EF 1= (EDV –V1) / EDV x 100 % 
where EDV is end-diastolic volume and V1 is volume at time of peak AV flow. 
Intra- and inter-observer variability in measurements of EF1 was assessed in 18 
randomly selected subjects by measurements repeated 2 months apart by 2 observers with the 
coefficient of variation defined as the standard deviation of difference in measures expressed 
as a percentage of the mean measurement. 
Statistical Analysis 
Continuous variables were tested for normality, and those following a Gaussian distribution 
were presented as meansstandard deviation (SD). Other variables were presented as medians 
and inter-quartile range. Comparisons between groups were made by Student’s t-test for 
continuous variables or by 2 test for categorical variables. Receiver-operating characteristic 
analysis was performed to examine the sensitivity and specificity of measures for events and 
the best cut-off value for predicting events was determined to maximise values of  sensitivity 
and specificity. Kaplan-Meier curves were used to examine cumulative event rates and the 
difference between groups was tested using a log rank test. Univariate Cox regression analysis 
was performed to identify potential predictors of events. Multivariate Cox proportional 
hazards models were used to test the independent value of echocardiographic measures for 
predicting future events. Analyses were repeated for the total population and in patients with 
moderate, severe, and discordant AS and in patients with EF in the lowest tertile. A two-tailed 
P-value of <0.05 was considered statistically significant. We assessed hazard ratios after 2 
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years of follow-up because this is a timeframe over which risk would inform clinical 
management (and ultimately all patients have events). All above statistical analyses were 
performed using SPSS 24 for Mac (SPSS Inc. Chicago, IL, USA). Categorical net 
reclassification improvement (assessed using the R software packages SurvIDINRI V1.1-1, 
Hajime Uno) was used to determine the added value of EF1 to conventional indices in 
predicting events. 
Results 
Patient characteristics and major events 
Three hundred and thirty-three patients meeting the inclusion criteria were identified of which 
115 were excluded from the final analysis, due to arrhythmias (n=28), more than moderate 
valve disease other than AS (n=37), loss to follow-up (n=21) and suboptimal echo image 
(n=29) (Figure 2). Thus, a total of 218 asymptomatic patients including 73 (33.5%) with 
moderate AS, 49 (22.5%) with severe AS and 96 (44.0%) with discordant AS were included 
in the final analysis. The aetiology of AS was degenerative 82.1%, congenital (bicuspid aortic 
valve) 17.4%, and uncertain 0.5%. The majority of patients who developed symptoms 
(n=102) during follow-up either underwent AVR (88/102) or died (11/102) whilst waiting for 
surgery shortly after developing symptoms. Only 3 patients developed symptoms without 
having AVR (because of unacceptable risk). In total 143 (65.6%) patients experienced an 
event after a median follow up of 33.4 months (IQR 21.0-51.2 months), including 89 (40.8%) 
surgical AVR, 17 (7.8%) transaortic AVR, 3 (1.4%) balloon aortic valvuloplasty, 2 (0.9%) 
hospitalisation due to heart failure and 32 (14.7%) death (before AVR or valvuloplasy). In 
patients with coronary artery disease, 13 had both CABG and AVR but the primary indication 
for surgery was AVR in all 13 patients. Event-free survival was 70.6%, 43.1% and 17.0% at 
2, 3 and 5 years respectively. The proportion of patients experiencing events was related to 
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the severity of AS (47.9%, 89.8% and 66.7% in patients with moderate, severe and discordant 
AS, respectively).  
EF1 and other echocardiographic measures 
Baseline clinical characteristics and echocardiographic data of patients with moderate, severe 
and discordant AS according to events are shown in Table 1. EF and GLS were not 
significantly different in the three groups.  The intra-observer and inter-observer coefficients 
of variation for EF1 were 6.73.6% and 9.86.1%, respectively. Absolute difference in EF1 
was 2.9% and 2.1% between and amongst observers (Figure S2). EF1 was negatively 
associated with AV MPG (=-0.192, p=0.005) with or without adjustment for age, gender, 
EF, GLS, LVMi and TPAVF/ejection time ratio. EF1 was the lowest in patients with severe 
AS (24.811.7%), compared to those with discordant (27.89.5%) and moderate AS 
(30.89.2%). 
When comparing those with events to those without events, EF1 was reduced in all 3 
groups and, in those with severe and discordant AS, was the only measure of systolic function 
that was reduced. In patients with moderate AS, MPG was significantly greater and AVAi 
smaller in patients with compared to those without events; SVi was significantly lower and 
GLS was significantly impaired in those with events compared to those without events. The 
percentage of patients with coronary artery disease and chronic kidney disease was also 
higher in those with events compared to those without events (Table 1).  
Prediction of major events by EF1 and other echocardiographic measures 
ROC curve analyses of EF1, GLS, MPG, AVAi, SVi and TAFR for predicting the primary 
outcome at 2 years are shown in Figure 3. The area under the curve (AUC) was the largest for 
EF1 (0.927, p<0.0001), followed by EF, MPG, GLS, AVAi, SVi and TAFR and the AUC for 
EF1 was significantly greater than that for the other predictors (p<0.0001). A cut-off value of 
25% for EF1 had a sensitivity of 87.1% and a specificity of 90.0% for prediction of events. 
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For GLS a cut off-value of -15% had a sensitivity of 56.5% and a specificity of 66.7%.  The 
incremental value of EF1 to a model including EF, GLS, LVMi and MPG, in terms of net 
reclassification was 67.3 % (95% confidence interval [CI]:  50.5-77.7%, p<0.001). 
Kaplan-Meier analysis showed that EF1 was a strong predictor of events in the total 
population over the whole follow-up period (Figure 4a).  When EF1 was less than 25%, the 1-
year, 2-year and 5-year event rates were 36.2%, 78.3% and 94.2%, respectively, compared to 
1.3%, 6.7% and 77.9% in patients with EF1≥25%. When comparing tertiles of the distribution 
of EF1, only 2/72 (2.8%) patients in the upper tertile had an event at 2 years whereas 53/73 
(72.6%) of patients in the lower tertile had events. EF1 was a stronger predictor of events than 
GLS (Figure S1). EF1 had strong predictive value in all patients irrespective of severity 
(moderate, severe or discordant, Figure 4b-4d). In the discordant group, EF1 was a stronger 
predictor of events (p<0.001) than GLS (p=0.049, Figure 5a), SVi or TAFR (Figure 5b and 
5c). 
On univariate Cox regression analysis several measures of AS severity (MPG and 
AVAi) and of LV systolic function (EF, GLS and SVi) as well as LVMi, LAVi and TPAVF 
(table 2) were related to events at 2-years in the the total population. However,  EF1 was more 
strongly related to events and the hazard ratio for each 1% increase in EF1 was 0.888 (95% 
CI: 0.865-0.911, p<0.001). Heart rate and ejection time were not significantly related to 
events, with TPAVF the only timing variable significantly related to events. In multivariate 
models 1 the independent predictive values of EF1 with GLS, MPG and LVMi were tested. In 
the total population, both MPG and EF1 were independently predictive of events but EF1 was 
more strongly predictive than MPG (table 2). In model 2, when all significant predictors in 
univariate analysis were entered, EF1 remained the most significant predictor of events (table 
2) with the hazard ratio for EF1 unchanged despite adjustment for these additional variables. 
This was also the case when measures of systolic function were added sequentially in a 
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forward step-wise analysis (tables S2). When an alternate end-point comprising symptoms, 
hospitalisation or death was considered hazard ratios were unchanged (HR: 0.882, 95% CI: 
0.860-0.906; p<0.001 compared to 0.885, 95% CI 0.863-0.903, p<0.001 when AVR was used 
in the end-point). 
When considering EF1 as a categorical variable (EF1< 25% vs. EF1 ≥ 25%) the HR 
was 27.7 (95%CI:13.1-58.7, P<0.001) unadjusted and 24.4 (95%CI:11.3-52.7, P<0.001), 
adjusted for other echocardiographic measures including GLS, for 2-year events in the total 
population. In patients with EF in the lowest tertile, EF1 remained as the strongest predictor 
(HR: 0.846, 95% CI: 0.802-0.894, p<0.001). Forcing heart rate or ejection time into the final 
model made no significant difference to the predictive value of EF1 (data not shown).  
EF1 was also the strongest predictor of events in all groups with a similar HR to that 
in the total population. In the discordant group, EF1 was the only significant predictor of 
events (HR: 0.897, 95% CI: 0.866-0.930, p<0.001, table 2) and in patients with moderate and 
severe AS, EF1 remained a strong predictor in both univariate and multivariable models (table 
S1).  
Prediction of All-cause mortality 
Thirty-two patients died before intervention with a median follow up of 20.8 months (IQR 
13.7-34.8 months). One-year and two-year mortality rates in all patients with a reduced EF1 
(<25%) were 7.2% (n=5) and 21.7% (n=15) compared with 0.7% (n=1) and 2.7% (n=4) in 
patients with EF1≥25% (log rank 46.3, P<0.0001, Figure 6). HR for all-cause mortality at 2 
years for EF1< 25% vs. EF1 ≥ 25% in the total population were 17.5 (5.7-53.3) unadjusted 
and 17.4 (5.5-55.2) when adjusted for MPG, GLS, LVMi and TAFR. TAFR had modest 
predictive value for all-cause mortality in univariate cox regression analysis (HR 0.993 
(0.986-0.999), P=0.018) but was not significantly associated with mortality when EF1 was 
included in the multivariate model. 
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Discussion 
In the present study we hypothesised that, in patients with asymptomatic AS and preserved 
EF, EF1, a measure of early systolic function up to the time of maximal AV flow, would have 
greater prognostic impact than measures calculated to end-systole. We showed a striking 
hazard ratio of 27.7 (95% CI: 13.1-58.7) for EF1<25% in predicting a major event within 2 
years of presentation. EF1 was superior to 2D GLS and other measures of LV or aortic valve 
function (including newer indices of valve function derived from timing of aortic valve flow 
such as TPAVF (17)). There is a trend towards prophylactic surgery in asymptomatic severe 
AS (18,19) and it is possible that EF1 could be used to guide this decision.   
 EF1 was equally strongly predictive of events in groups classified as moderate, severe 
and discordant. Within the discordant group, current guidelines advocate the use of SVi to 
sub-divide this group into moderate or low-flow severe AS (3,14,15). However, we found no 
predictive value of SVi within this group. Similarly, other measures of LV systolic function, 
flow rate, and GLS did not predict events in the discordant group.  This may be because these 
measures are calculated over the whole of systole and do not capture the reduction in early 
systolic function which we have shown is prognostically important. A surprising finding was 
that EF1 was predictive of major events in patients with moderate AS. Only a minority of 
patients with high-gradient severe AS are thought to progress to low-flow, low gradient 
severe AS (20) and it is known that LV function can be affected by coronary artery disease 
and other risk factors (21,22). The present study provides further corroborative evidence that 
LV systolic function can change independently of valve function, and it is notable that in our 
study patients with moderate AS and major events had a higher prevalence of CAD than those 
without events.  
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Whilst our primary outcome was the prediction of events in asymptomatic patients 
with AS, it is notable that EF1 was also predictive of all-cause mortality in the total 
population, so that 2-year mortality for all patients in the lowest tertile of EF1 was 21.7%, 
compared to 2.7% for patients with EF1 in the highest tertile. That TAFR was predictive of 
all-cause mortality when considered alone but not when in addition to EF1 is consistent with 
previous studies (16,23) and again highlights the importance of events early in systole.  
There are important limitations to our study that should be considered. There was 
some loss to follow-up of a relatively small number of patients. EF1 was measured by two 
trained observers retrospectively.  Patients with a suboptimal echo image in which neither 
EF1 nor EF could be measured with confidence were excluded from the study. Measurements 
made in clinical use may exhibit more variability, although this will be reduced by 
improvements in imaging technology that will allow automatic determination of EF1. We 
compared EF1 with 2D rather than 3D GLS and 3D GLS is a better predictor of events in AS 
than 2D GLS (24). Some of the outcomes in our study may be dependent on the specific 
characteristics of our cohort and prospective replication in other cohorts will be required 
before the measurement can be reliably used to inform clinical management. Circulating 
biochemical biomarkers such as brain natriuretic peptide (BNP), have also been shown to 
predict events in asymptomatic AS (25,26) but may lack specificity. Further prospective 
studies will be required to determine the place of EF1 relative to other biomarkers in the risk 
stratification of AS, particularly in the various sub-groups of AS and to determine the 
importance of concurrent coronary artery disease. 
 In conclusion, EF1 is a simple robust measure of early systolic function, predicting 
major events in patients with asymptomatic AS and preserved EF. If the findings of the 
present study are replicated in other cohorts, it could be used to inform clinical management 
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of AS. It may also be useful for identifying early systolic dysfunction in other conditions 
where progression to late systolic function is associated with a poor prognosis.  
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Perspectives 
Competency in medical knowledge 
In patients with AS, a reduction in EF is associated with a poor prognosis and is a strong 
indication for intervention. Mechanosensing within myocytes may, however, act to preserve 
EF so that a fall in EF is a late event in the evolution of systolic dysfunction. EF1 is a novel 
measure of early systolic function that may be more sensitive than EF in detecting systolic 
dysfunction. 
Translational Outlook 1 
The present study is the first to demonstrate the independent prognostic value of EF1 in 
asymptomatic patients with preserved EF and moderate or severe AS. EF1 was superior to 
other measures of LV or aortic valve function. If confirmed in other cohorts EF1 could be 
used as a marker of increased risk to aid decision on prophylactic surgery in asymptomatic 
severe AS.   
Translational Outlook 2 
In patients with moderate AS a reduced EF1 appears to identify a high-risk group and it is 
possible that these should be offered further investigation for coronary disease or treatment of 
other determinants of LV dysfunction for example systemic hypertension. This may help us to 
better manage LV dysfunction beginning despite only moderate AS and may also improve LV 
recovery when aortic valve intervention is judged to be indicated. Patients with discordant 
velocity/gradient and AVA measurements are hard to classify and manage.  Our preliminary 
results suggest that EF1 better classifies these than conventional measures, notably SVi.  
Translational Outlook 3 
The present study provides proof-of-concept for early systolic function as an important risk 
factor in other conditions that may be characterised by progression from early systolic to late 
systolic dysfunction.  
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Figure legends 
Figure 1. Measurement of EF1 
Left ventricular volume measured from echo apical views and aortic valve (AV) flow 
measured from apical 5-chamber view using continuous wave Doppler. First-phase ejection 
fraction (EF1) was defined as percentage change in volume change from end-diastole (EDV) 
to volume (V1) occurring at time of peak aortic valve flow. EDV and V1 were obtained by 
Simpson’s rule (see text for details). In this figure the entire time-varying LV volume curve is 
displayed to illustrate concept of EF1 (via a wall-tracking analysis performed in a single 
case). 
 
Figure 2. Study population flow chart 
218 out of 333 asymptomatic patients with moderate to severe aortic stenosis were included in 
the final analysis. 
 
Figure 3. Receiver-Operating Characteristic (ROC) curve analysis 
Receiver-Operating Characteristic (ROC) curve analysis for prediction of events at 2-year 
follow up in the total population. EF, ejection fraction; GLS, global longitudinal strain; MPG, 
mean pressure gradient; AVAi, aortic valve area index; SVi, stroke volume index; TAFR, 
trans aortic flow rate. 
 
Figure 4. Kaplan-Meier curves according to EF1  
Kaplan-Meier event-free survival curves according to EF1 (cut off value 25%) for a) total 
population (n=218); b) patients with moderate AS (n=73); c) patients with severe AS (n=49) 
and d) discordant AS (mean pressure gradient < 40mmHg and aortic valve area <1.0cm2 , 
n=96). 
 
Figure 5. Kaplan-Meier curves according to GLS, SVi and TAFR 
Kaplan-Meier event-free survival curves according to a) Global longitudinal strain (GLS), b) 
stroke volume index (SVi) and c) trans-aortic flow rate (TAFR) in the discordant group (mean 
pressure gradient < 40mmHg and aortic valve area <1.0cm2). 
 
Figure 6.  Kaplan-Meier curves for all-cause mortality 
Kaplan-Meier curves for all-cause mortality for the total population: a) EF1 and b) GLS. 
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Table 1. Baseline patient characteristics and echocardiographic measures for the total population 
according to severity of aortic stenosis. 
  
Events 
(n=35) 
No Events 
(n=38) 
P  
Events 
(n=44) 
No Events 
(n=5) 
P  Events (n=64) 
No Events 
(n=32) 
P 
  Moderate (n=73)      Severe (n=49)                Discordant (n=96) 
Age (years)  68.612.3 63.417.1 0.142  69.212.4 69.75.0 0.936  69.313.2 72.812.9 0.215 
Male Sex (%)  77.1% 57.9% 0.080  40.9% 40.0% 0.969  50.0% 50.0% 1.000 
BMI (kg/m2)  30.06.1 28.03.7 0.100  27.45.2 25.73.3 0.486  27.94.7 27.24.6 0.508 
Heart rate (bpm)  6915 7213 0.347  7313 665 0.255  7012 6510 0.036 
SBP (mmHg)  14416 13620 0.041  14024 14029 0.975  13624 13015 0.206 
DBP (mmHg)  7611 7511 0.566  7310 7722 0.430  7111 7010 0.490 
Risk Factors             
   Smoking (%)  31.4% 26.3% 0.630  34.1% 40.0% 0.793  39.1% 31.2% 0.453 
   Hypertension (%)  94.3% 81.6% 0.099  79.5% 80.0% 0.981  76.6% 62.5% 0.149 
   DM (%)  22.9% 21.1% 0.852  22.7% 0.0% 0.232  17.2% 15.6% 0.846 
   CAD (%)  65.7% 21.1% <0.001  43.2% 40.0% 0.892  34.3% 37.5% 0.763 
   CKD (%)  28.6% 0.05% 0.007  18.2% 0.0% 0.297  32.8% 40.6% 0.451 
Medications             
   ACE/ARB (%)  25.7% 39.5% 0.211  15.9% 0.0% 0.335  20.3% 25.0% 0.600 
   Betablocker (%)  31.4% 23.7% 0.459  22.7% 20.0% 0.890  14.1% 18.8% 0.551 
   CCB (%)  28.5% 13.2% 0.103  36.4% 20.0% 0.466  18.8% 25.0% 0.477 
   Diuretic (%)  34.3% 21.1% 0.205  34.1% 20.0% 0.524  23.4% 14.3% 0.374 
   Statins (%)  65.7% 63.2% 0.820  70.5% 100% 0.156  56.3% 56.3% 1.000 
   Aspirin (%)  40.0% 31.6% 0.453  40.9% 40.0% 0.969  29.7% 34.3% 0.640 
Echocardiography             
   MPG (mmHg)  27.16.3 24.25.5 0.041  49.111.0 46.96.3 0.654  28.66.1 27.45.8 0.353 
   AVA (cm2)  1.230.22 1.280.30 0.439  0.840.27 0.770.18 0.593  0.790.13 0.800.16 0.822 
   AVAi (cm2/m2)  0.630.12 0.690.15 0.043  0.440.13 0.450.09 0.891  0.430.09 0.440.09 0.813 
   EDV (ml)  100.329.9 103.530.8 0.651  99.538.5 91.248.3 0.658  87.132.3 86.731.0 0.955 
   SVi (ml/m2)  32.98.9 37.39.4 0.046  32.810.7 36.918.9 0.453  30.010.0 30.99.6 0.643 
   SVi-VTI (ml/m2)  46.110.5 47.010.7 0.729  42.410.8 45.98.3 0.487  33.87.5 33.76.7 0.923 
   LVMi (g/m2)  104.324.8 98.925.7 0.362  120.242.9 112.837.4 0.712  97.337.1 93.332.2 0.604 
   EF (%)  65.97.8 68.08.0 0.253  63.48.6 68.24.2 0.225  64.28.3 66.18.05 0.268 
   EF1 (%)  26.09.6 35.26.1 <0.001  23.511.6 36.25.2 0.021  25.110.1 33.15.0 <0.001 
   GLS (%)  -15.53.7 -18.24.5 0.007  -15.04.6 -15.81.9 0.700  -15.95.1 -17.43.1 0.125 
   S wave (cm/s)  8.12.4 8.42.0 0.518  7.42.0 8.82.6 0.151  7.71.8 7.91.7 0.582 
   E/e’  11.04.1 11.34.8 0.777  12.44.0 8.42.3 0.035  12.06.8 10.45.2 0.261 
   LAVi (ml/m2)  33.212.3 29.68.7 0.162  36.115.2 31.510.8 0.520  31.713.6 30.713.1 0.716 
   TPAVF (ms)  125.425.3 124.323.2 0.838  145.424.6 130.023.4 0.189  132.224.9 134.820.2 0.619 
   TPAVF/ET  0.420.08 0.430.09 0.775  0.480.08 0.430.08 0.166  0.440.09 0.440.08 0.963 
Values are meanSD. P values are the difference between Events and no Events for each group. 
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AS, aortic stenosis; BMI, body mass index; bpm: beats per minute; SBP, systolic blood pressure; DBP, 
diastolic blood pressure; DM, Diabetes Mellitus; CAD, coronary artery disease; CKD, chronic kidney 
disease; ACE, angiotensin-converting-enzyme; CCB, calcium-channel blocker; MPG, mean pressure 
gradient; AVA, aortic valve area; AVAi, aortic valve area index; EDV, end-diastolic volume; SVi, stroke 
volume indexed to body surface area; VTI: velocity time integral; LVMi, left ventricular mass index; EF, 
ejection fraction; EF1, first phase ejection fraction; GLS, global longitudinal strain; E/e’, early mitral 
filling / tissue Doppler mitral annulus motion; LAVi, left atrial volume index; TPAVF, time to peak 
aortic valve flow; ET, ejection time.   
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Table 2. Univariate and multivariate analysis of predictors of events 
 HR CI (95%) P value  HR CI (95%) P value 
 Total population 
(n=218) 
  Discordant 
(n=96) 
 
Univariate        
    Age  1.011 0.999 – 1.023 0.061  0.868 0.981 – 1.016 0.868 
    Gender 0.883 0.631 – 1.235 0.466  0.909 0.555 – 1.490 0.705 
    BMI  1.023 0.988 – 1.059 0.199  1.017 0.966 – 1.071 0.515 
    Smoking 1.223 0.867 – 1.725 0.251  1.180 0.713 – 1.952 0.520 
    Hypertension 1.302 0.850 – 1.993 0.225  1.509 0.845 – 2.695 0.165 
    Diabetes 1.104   0.734 – 1.662 0.643  1.174 0.612 – 2.252 0.630 
    CAD 1.250 0.896 – 1.743 0.189  0.884 0.524 – 1.490 0.643 
    CKD 0.464 0.794 – 1.660 0.464  0.844 0.399 – 1.425 0.525 
    MPG 1.031 1.019 – 1.043 <0.001  1.008 0.968 – 1.050 0.709 
    AVAi 0.075 0.023 – 0.249 <0.001  0.193 0.013 – 2.924 0.236 
    LVMi 1.006 1.001 – 1.011 0.022  1.002 0.995 – 1.010 0.521 
    EF 0.962 0.941 – 0.983 0.001  0.966 0.936 – 0.997 0.033 
    Heart Rate 1.001 0.988 – 1.013 0.911  1.005 0.985 –1.027 0.615 
    Ejection time 1.002 0.997 – 1.007 0.045  1.000 0.992 – 1.008 0.970 
    SVi 0.974 0.957 – 0.992 0.005  0.985 0.957 – 1.013 0.298 
    TAFR 0.998 0.995 – 1.000 0.082  0.999 0.994 –1.003 0.576 
    GLS 1.091 1.046 – 1.137 <0.001  1.053 0.991 – 1.118 0.095 
    LAVi 1.023 1.009 – 1.036 0.001  1.013 0.994 – 1.032 0.195 
    TPAVF 1.007 1.000 – 1.014 0.038   0.707 0.986 – 1.010 0.707 
    TPAVF/ET 4.930 0.671 – 36.231 0.117  0.623 0.027 – 14.470 0.768 
    EF1 0.877 0.857 – 0.897 <0.001  0.901 0.872 – 0.931 <0.001 
Multivariate Model 1        
    LVMi 1.002 0.997 – 1.008 0.347  1.001 0.993 – 1.009 0.779 
    MPG 1.014 1.002 – 1.026 0.022  0.982 0.942 – 1.025 0.410 
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    GLS 1.010 0.965 – 1.057 0.662  0.996 0.932 – 1.065 0.909 
    EF1 0.884 0.863 – 0.906 <0.001  0.897 0.866 – 0.930 <0.001 
Multivariate Model 2        
    MPG 1.008 0.994 – 1.022 0.249  – – – 
    AVAi 0.324 0.083 – 1.268 0.106  – – – 
    LVMi 1.005 0.999 – 1.011 0.092  – – – 
    EF 1.027 0.999 – 1.055 0.062  1.011 0.977 – 1.046 0.527 
    SVi 0.974 0.954 – 0.994 0.012  – – – 
    GLS 1.025 0.973 – 1.079 0.354  – – – 
    LAVi 1.013 0.998 – 1.028 0.094  – – – 
   TPAVF 0.693 0.994 – 1.009 0.693  – – – 
    EF1 0.885 0.863 – 0.903 <0.001  0.896 0.865 – 0.930 <0.001 
AS, aortic stenosis; HR, hazard ratio; CI, confidence interval; BMI, body mass index; CAD, 
coronary artery disease; CKD, chronic kidney disease; AV, aortic valve; MPG, mean pressure 
gradient; AVAi, aortic valve area index; LVMi, left ventricular mass index; EF, ejection 
fraction; SVi, stroke volume indexed to body surface area; TAFR: trans-aortic flow rate;  GLS, 
global longitudinal strain; LAVi, left atrial volume index; TPAVF: time to peak aortic flow; ET: 
ejection time; EF1, first phase ejection fraction.  
 






